Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors, Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical Trials

BACKGROUND: Cancer, with sustained high mortality, is a worldwide threat to public health. Despite the survival benefit over conventional therapies shown in immune checkpoint inhibitor (ICI), only a minority of patients benefit from single ICI. But combination therapy holds the promise of achieving...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Leyin, Sun, Leitao, Zhou, Yiwen, Yu, Jieru, Lin, Yingying, Wasan, Harpreet S., Shen, Minhe, Ruan, Shanming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947606/
https://www.ncbi.nlm.nih.gov/pubmed/33718135
http://dx.doi.org/10.3389/fonc.2021.575457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947606/
https://www.ncbi.nlm.nih.gov/pubmed/33718135
http://dx.doi.org/10.3389/fonc.2021.575457

Ejemplares similares